9 Questions
What are the symptoms of Stable Ischemic Heart Disease (SIHD)?
Neck or jaw pain, shoulder or arm pain, fast heartbeat, shortness of breath, nausea and vomiting, sweating, fatigue
What are some risk factors for Ischemic Heart Disease?
Hypertension
Strict glycemic control is beneficial for patients with advanced Chronic Kidney Disease (CKD).
False
Behavioral modification therapy for Ischemic Heart Disease includes patient education, diet, physical activity, and smoking ______________.
cessation
What are the symptoms of stable ischemic heart disease (SIHD)?
Angina Pectoris, neck or jaw pain, shoulder or arm pain, fast heartbeat, shortness of breath, nausea, vomiting, sweating, fatigue
What are common risk factors for the development of ischemic heart diseases?
Age, male gender, and diabetes mellitus
Behavioral modification therapy is an essential component for all risk factors associated with ischemic heart diseases.
True
What is the primary purpose of vasculoprotective therapy in the treatment of ischemic heart diseases?
To reduce the risk of future cardiovascular events
Which pharmacotherapy is considered essential for alleviating acute symptoms of myocardial ischemia?
Nitrates
Study Notes
Stable Ischemic Heart Disease (SIHD)
- SIHD is characterized by ischemia (reduced blood flow) but not infarction (heart tissue death)
Symptoms of SIHD
- Angina pectoris or stable angina
- Neck or jaw pain
- Shoulder or arm pain
- Fast heartbeat
- Shortness of breath (on exertion)
- Nausea and vomiting
- Sweating
- Fatigue
- Exclude: new chest pain, chest pain at rest, or positive biomarkers
Risk Factors for SIHD
- Atheroma in one or more coronary arteries
- BMI > 27.5 kg/m²
- Age and male sex
- Diabetes mellitus
- Smoking
- Family history
- Á LDL and/or â HDL
- Hypertension
- Alcohol abuse
Risk Stratification
- 2-3 modalities recommended for stratification
Treatment Outcomes and Approach
- Prevent acute coronary syndrome (MI) and death
- Alleviate acute symptoms of myocardial ischemia
- Prevent recurrent symptoms of myocardial ischemia
- Prevent disease progression
- Avoid or minimize adverse treatment effects
Pharmacotherapy
- Vasculoprotective therapy:
- Behavioral modification therapy for all risks
- Risk factor modification (ACEIs and statins)
- Antiplatelet therapy
- Anti-ischemic pharmacotherapy:
- Beta blockers, nitrates, calcium-channel blockers, and trimetazidine
- Others: ivabradine, nicorandil, ranolazine, SGLT2, and GLP-1RA
Myocardial Revascularization
- Must be done in high-risk patients
Special Populations
- Chronic kidney disease:
- Limited data on efficacy and role of pharmacotherapy and revascularization
- Importance of lifestyle modification, good glycemic and blood pressure control to reduce CV events
- Strict glycemic control may not benefit patients with advanced CKD
- Benefit of statins in moderate CKD not RRT
- Some evidence shows CV risk reduction with aspirin in individuals with eGFR < 30 mL/min/1.73m²
Stable Ischemic Heart Disease (SIHD)
- SIHD is characterized by ischemia (reduced blood flow) but not infarction (heart tissue death)
Symptoms of SIHD
- Angina pectoris or stable angina
- Neck or jaw pain
- Shoulder or arm pain
- Fast heartbeat
- Shortness of breath (on exertion)
- Nausea and vomiting
- Sweating
- Fatigue
- Exclude: new chest pain, chest pain at rest, or positive biomarkers
Risk Factors for SIHD
- Atheroma in one or more coronary arteries
- BMI > 27.5 kg/m²
- Age and male sex
- Diabetes mellitus
- Smoking
- Family history
- Á LDL and/or â HDL
- Hypertension
- Alcohol abuse
Risk Stratification
- 2-3 modalities recommended for stratification
Treatment Outcomes and Approach
- Prevent acute coronary syndrome (MI) and death
- Alleviate acute symptoms of myocardial ischemia
- Prevent recurrent symptoms of myocardial ischemia
- Prevent disease progression
- Avoid or minimize adverse treatment effects
Pharmacotherapy
- Vasculoprotective therapy:
- Behavioral modification therapy for all risks
- Risk factor modification (ACEIs and statins)
- Antiplatelet therapy
- Anti-ischemic pharmacotherapy:
- Beta blockers, nitrates, calcium-channel blockers, and trimetazidine
- Others: ivabradine, nicorandil, ranolazine, SGLT2, and GLP-1RA
Myocardial Revascularization
- Must be done in high-risk patients
Special Populations
- Chronic kidney disease:
- Limited data on efficacy and role of pharmacotherapy and revascularization
- Importance of lifestyle modification, good glycemic and blood pressure control to reduce CV events
- Strict glycemic control may not benefit patients with advanced CKD
- Benefit of statins in moderate CKD not RRT
- Some evidence shows CV risk reduction with aspirin in individuals with eGFR < 30 mL/min/1.73m²
This quiz assesses your understanding of stable ischemic heart disease, including treatment algorithms, interventions, and long-term treatment considerations.
Make Your Own Quizzes and Flashcards
Convert your notes into interactive study material.
Get started for free
